The Chinese Stroke Association scientific statement:intravenous thrombolysis in acute ischaemic stroke
作者机构：Department of NeurologyHuashan Hospital affiliated to Fudan UniversityShanghai ShiChina Department of NeurologyBeijing Tiantan Hospital affiliated to Capital Medical UniversityBeijingChina Department of Neurology and Stroke CenterFirst Affiliated HospitalJinan UniversityGuangzhou ShiChina On behalf of the CSA Scientific Statement on Intravenous Thrombolysis in Acute Ischemic Stroke Writing Group
出 版 物：《Stroke & Vascular Neurology》 (卒中与血管神经病学（英文）)
年 卷 期：2017年第2卷第3期
页 面：147-159页
核心收录：
基 金：CCMAD Pfizer AstraZeneca Bayer Sanofi Boehringer Ingelheim National Natural Science Foundation of China, NSFC, (81671167) National Natural Science Foundation of China, NSFC Guangzhou Science and Technology Program key projects, (2014Y2-00505, 201508020004) Guangzhou Science and Technology Program key projects
主 题：thrombolysis intravenous acute
摘 要：The most effective medical treatment for acute ischaemic stroke(AIS)is to offer intravenous thrombolysis during the ultra-early period of time after the *** based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS,the rate of thrombolysis for AIS in China remained around 2.4%,and the rate of intravenous tissue plasminogen activator usage was only about 1.6%in real *** indication of thrombolysis for AIS has been expanded,and contraindications have been reduced with recently published *** order to facilitate the standardisation of treating AIS,improve the rate of thrombolysis and benefit patients who had a stroke,Chinese Stroke Association has organised and developed this scientific statement.
维普期刊数据库